Webinar: Key insights on the clinical to commercial transition for autologous therapies

The journey from clinical to commercial for vein-to-vein autologous therapies can be challenging and complex

Advancing cell and gene therapies

When healthcare advances, so must the processes to connect patients to the therapies they need. And because a rapidly changing cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.

Start a conversation